Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.45

-2.7%

Jan 8 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (590)	1/28/2000 1:46:00 AM
From: N/E PATSFAN	of 52153

[immt] >> Immtech's data indicates that rmCRP therapy, like angiogenesis inhibitor therapy, targets blood vessels. Unlike angiogenesis inhibitors, which block the growth of new vessels, rmCRP works to strengthen existing normal tissues. Immtech's biological therapeutics program is uniquely focused on strengthening the human body's most basic immune system defenses, helping the body reestablish effective tissue barriers to the entry and spread of disease throughout the body. Strengthened tissues also allow the body's intrinsic immune system to more effectively and efficiently combat disease << There's an interesting and "greener" approach to combat disease - no wonder you've got an interest in CRP! It is a little pricey right now with a pull back in the markets likely but I'll start to acquire some asap but with the small float (2.6M), that may be difficult... thanks as usual, NEPF

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next